ATM and Ataxia-telangiectasia: Although heterozygous ATM mutation carriers do not have ataxia-telangiectasia, they have a 17–52% lifetime risk of developing breast cancer.[6] However, despite association of ATM with ovarian cancer in recent literature[7], carriers are not routinely counseled for this risk as exact risks are unknown.